Table 4.
HA2 analogues and other sequence variations in CPPs to overcome lysosomal entrapment.
Name | Amino acid sequence | a.a. # | Structural order | Cargo | Purity | Efficiency | Ref. |
---|---|---|---|---|---|---|---|
HA2 analogues | |||||||
GLFEAIEGFIENGWEGMIDGWYG | 23 | pHA2-p53-R9 | p53 | N.A. | 5x | [70] | |
| |||||||
GDIMGEWGNEIFGAIAGFLG | 20 | pTat-Cre, pTat-HA2 | No cargo | N.A. | 2–6x | [71] | |
| |||||||
GLFEAIEGFIENGWEGMIDGWYG | 23 | HA2-Tat | PM10 | N.A. | 0.5–1x | [72] | |
| |||||||
pTat-HA-hARC or pTat-HA-β-gal | pTat-HA-hARC or pTat-HA-β-gal | β-gal, ARC | N.A. | N.A. | [73] | ||
| |||||||
GLFEAIAEFIEGGWEGLIEGCAKKK | 25 | HA2-NT (NT = neurotensin) |
NT | >90% | 22% | [74] | |
| |||||||
GLFGAIAGFIENGQWGMIDG | 20 | HA2-Tat | FP | N.A. | N.A. | [75] | |
| |||||||
GLFEAIEGFIENGWEGMIDGWYG | 23 | HA2-Tat | Shepherdin | >90% | 3x | [76] | |
| |||||||
GLFEAIEGFIENGWEGMIDGWYGC GLFEAIEGFIENGWEGMIDGWYGC (dimeric) |
48 | EGFR siRNA/LF/diNF-7 |
EGFR siRNA |
N.A. | >2x | [77] | |
| |||||||
GLFEAIEGFIENGWEGMIDGWYG | 23 | CPP-HA2 | mCherry | N.A. | 80–90x | [78] | |
| |||||||
GLFEAIEGFIENGWEGMIDGWYG | 23 | GALA-INF | Luciferase | N.A. | >1000x | [79] | |
| |||||||
GLLEALAELLE | 11 | HA2-CPP | FP | >95% | 2x | [80] | |
| |||||||
Sequence variations in CPPs | |||||||
10H | CHHHHHRKKRRQRRRRHHHHHC | 22 | C-5H-Tat-5H-C | Luciferase | >98% | >7000x | [81] |
| |||||||
HR9 | CHHHHHRRRRRRRRRHHHHHC | 21 | C-5H-R9-5H-C | DNAs, FPs, QDs | 87% | 20x | [43] |
| |||||||
PasR8 | FFLIPKGRRRRRRRRGC | 17 | Pas-CPP | Alexa 488 | N.A. | 18x | [82] |
| |||||||
PR9 | FFLIPKGRRRRRRRRR | 16 | Pas-CPP | DNAs, FPs, QDs | 99% | 47.5x | [44] |
GALA | WEAALAEALAEALAEHLAEALAEALEALAA | 30 | GALA-EGFP | FITC | N.A. | 68x | [83] |
N.A. = not available.